Can adding venetoclax let CLL patients pause therapy?

NCT ID NCT06524375

Ongoing Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding venetoclax to standard BTK inhibitor therapy can help people with chronic lymphocytic leukemia (CLL) achieve very deep remission. The goal is to see if patients can then safely stop all treatment for a period. The study involves 118 adults who have been on a BTK inhibitor for at least 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax (a targeted drug) added to a BTK inhibitor (ibrutinib, acalabrutinib, or zanubrutinib)
What this could lead to: If successful, this could allow some CLL patients to stop treatment temporarily while keeping the disease under control.
What could go wrong: This is a small, early-phase trial without a comparison group. Adding venetoclax may increase side effects, and not all patients will achieve deep remission.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

American Oncology Partners of Maryland, PA

Bethesda, Maryland, 20817-1915, United States
Asante Rogue Regional Medical Center

Medford, Oregon, 97504-8332, United States
Astera Cancer Care East Brunswick

East Brunswick, New Jersey, 08816-4096, United States
Cancer Specialists of North Florida

Jacksonville, Florida, 32256-6932, United States
Dana-Farber Cancer Institute - Hematologic Oncology Treatment Center

Boston, Massachusetts, 02215-5418, United States
Fort Wayne Medical Oncology and Hematology, Inc

Fort Wayne, Indiana, 46804, United States
Highlands Oncology Group

Springdale, Arkansas, 72762, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Mission Blood and Cancer - MercyOne Cancer Center

Des Moines, Iowa, 50314-3030, United States
Nebraska Cancer Specialists

Omaha, Nebraska, 68130-2042, United States
Nebraska Cancer Specialists St Francis - Grand Island

Grand Island, Nebraska, 68803, United States
Ohio State University

Columbus, Ohio, 43210, United States
Oncology Hematology Care Inc - Cincinnati - USOR

Cincinnati, Ohio, 45236-2725, United States
Rocky Mountain Cancer Centers (Aurora) - USOR

Aurora, Colorado, 80012-5405, United States
San Juan Oncology Associates, PC

Farmington, New Mexico, 87401, United States
Tennessee Oncology - Midtown

Nashville, Tennessee, 37203, United States
Tennessee Oncology, PLLC - Chattanooga

Chattanooga, Tennessee, 37404, United States
Texas Oncology- Northeast Texas

Tyler, Texas, 75702, United States
Willamette Valley Cancer Institute and Research Center

Eugene, Oregon, 97401-6043, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.